Chaveli López
B, Gavaldá Esteve C, Sarrión Pérez MG. Dental treatment
considerations in the chemotherapy patient. J Clin Exp Dent. 2011;3(1):e31-42.
doi:10.4317/jced.3.e31
References
1.
López-Galindo MP, Bagán JV, Jiménez-Soriano Y, Alpiste F, Camps
C. Clinical evaluation of dental and periodontal status in a group of
oncological patients before chemotherapy. Med Oral Patol Oral Cir Bucal.
2006;11:E17-21.
2. Caribé-Gomes F, Chimenos-Küstner E, López-López J,
Finestres-Zubeldia F, Guix-Melcior B. Dental management of the complications of
radio and chemotherapy in oral cancer. Med Oral. 2003;8:178-87.
3. Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, et al.
Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004;100:2261-8.
doi:10.1002/cncr.20230
PMid:15139073
4. Hueso L, Sanmartín O, Nagore E, Botella-Estrada R, Requena C,
Llombart B, et al. Chemotherapy-induced acral erythema: a clinical and histopathologic
study of 44 cases. Actas Dermosifiliogr. 2008;99:281-90.
doi:10.1016/S0001-7310(08)74677-5
5. Stone R, Fliedner MC, Smiet AC. Management of oral mucositis in patients
with cancer. Eur J Oncol Nurs. 2005;9:S24-32.
doi:10.1016/j.ejon.2005.08.004
PMid:16202654
6. Hejna M, Köstler WJ, Raderer M, Steger GG, Brodowicz T, Scheithauer W,
et al. Decrease of duration and symptoms in chemotherapyinduced oral mucositis
by topical GM-CSF: results of a prospective randomised trial. Eur J Cancer.
2001;37:1994-2002.
doi:10.1016/S0959-8049(01)00132-0
7. Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients
who have cancer. Dent Clin North Am. 2008;52:61-77, viii.
doi:10.1016/j.cden.2007.10.002
PMid:18154865 PMCid:2266835
8. López-Castaño F, Oñate-Sánchez RE,
Roldán-Chicano R, Cabrerizo-Merino MC. Measurement of secondary
mucositis to oncohematologic treatment by means of different scale. Review. Med
Oral Patol Oral Cir Bucal. 2005; 10: 412-21.
9. Logan RM, Stringer AM, Bowen JM, Yeoh AS, Gibson RJ, Sonis ST, et al. The
role of pro-inflammatory cytokines in cancer treatmentinduced alimentary tract
mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev.
2007;33:448-60.
doi:10.1016/j.ctrv.2007.03.001
PMid:17507164
10. Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in
cancer patients: unanswered questions. Oral Oncol. 2003;39:91-100.
doi:10.1016/S1368-8375(02)00033-7
11. Raber-Durlacher JE, Elad S, Barasch A. Oral mucositis. Oral Oncol. 2010;46:452-6.
doi:10.1016/j.oraloncology.2010.03.012
PMid:20403721
12. Napeñas JJ, Brennan MT, Bahrani-Mougeot FK, Fox PC, Lockhart PB.
Relationship between mucositis and changes in oral microflora during cancer
chemotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103:48-59.
doi:10.1016/j.tripleo.2005.12.016
PMid:17178494
13. Antunes HS, Ferreira EM, Matos VD, Pinheiro CT, Ferreira CG. The Impact of
low power laser in the treatment of conditioning-induced oral mucositis: A
report of 11 clinical cases and their review. Med Oral Patol Oral Cir Bucal.
2008; 13: E189 -92.
14. Donnelly JP, Bellm LA, Epstein JB, Sonis ST, Symonds RP. Antimicrobial
therapy to prevent or treat oral mucositis. Lancet Infect Dis. 2003;3:405-12.
doi:10.1016/S1473-3099(03)00668-6
15. Clarkson JE, Worthington HV, Eden OB. Interventions for treating oral
candidiasis for patients with cancer receiving treatment. Cochrane Database
Syst Rev. 2004;(1):CD001972.
PMid:14973977
16. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE,
et al. Updated clinical practice guidelines for the prevention and treatment of
mucositis. Cancer. 2007;109: 820-31.
doi:10.1002/cncr.22484
PMid:17236223
17. Colella G, Cannavale R, Vicidomini A, Rinaldi G, Compilato D, Campisi G.
Efficacy of a spray compound containing a pool of collagen precursor synthetic
aminoacids (l-proline, l-leucine, l-lysine and glycine) combined with sodium
hyaluronate to manage chemo/ radiotherapy-induced oral mucositis: preliminary
data of an open trial. Int J Immunopathol Pharmacol. 2010;23:143-51.
PMid:20378002
18. Jensen SB, Mouridsen HT, Bergmann OJ, Reibel J, Brünner N, Nauntofte
B. Oral mucosal lesions, microbial changes, and taste disturbances induced by
adjuvant chemotherapy in breast cancer patients. Oral Surg Oral Med Oral Pathol
Oral Radiol Endod. 2008;106:217-26.
doi:10.1016/j.tripleo.2008.04.003
PMid:18554960
19. Hong CH, Napeñas JJ, Hodgson BD, Stokman MA, Mathers-Stauffer V,
Elting LS, et al. A systematic review of dental disease in patients undergoing
cancer therapy. Support Care Cancer. 2010 May 7.
20. Raber-Durlacher JE, Epstein JB, Raber J, van Dissel JT, van Winkelhoff AJ,
Guiot HF, et al. Periodontal infection in cancer patients treated with
high-dose chemotherapy. Support Care Cancer. 2002;10:466-73.
doi:10.1007/s00520-002-0346-3
PMid:12353125
21. Epstein JB, Tsang AH, Warkentin D, Ship JA. The role of salivary function
in modulating chemotherapy-induced oropharyngeal mucositis: a review of the
literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;94:39-44.
doi:10.1067/moe.2002.126018
22. Minicucci EM, Lopes LF, Crocci AJ. Dental abnormalities in children after
chemotherapy treatment for acute lymphoid leukemia. Leuk Res. 2003;27:45-50.
doi:10.1016/S0145-2126(02)00080-2
23. Bagán JV, Diz-Dios P, Gallego L, Infante-Cossío P,
Jiménez Y, Junquera LM, y cols. Recomendaciones para la prevención
de la osteonecrosis de los maxilares (ONM) en pacientes con cáncer
tratados con bisfosfonatos intravenosos. Med Oral Patol Oral Cir Bucal.
2008;13:161-7.
24. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et
al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates:
incidence and risk factors. J Clin Oncol. 2005;23:8580-7.
doi:10.1200/JCO.2005.02.8670
PMid:16314620
25. McLeod NM, Davies BJ, Brennan PA. Bisphosphonate osteonecrosis of the jaws;
an increasing problem for the dental practitioner. Br Dent J. 2007;203:641-4.
doi:10.1038/bdj.2007.1065
PMid:18065983
26. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G.
Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80
patients with multiple myeloma and other malignancies. Oral Oncol.
2008;44:857-69.
doi:10.1016/j.oraloncology.2007.11.012
PMid:18282788
27. Bagan J, Scully C, Sabater V, Jimenez Y. Osteonecrosis of the jaws in
patients treated with intravenous bisphosphonates (BRONJ): A concise update.
Oral Oncol. 2009;45:551-4.
doi:10.1016/j.oraloncology.2009.01.002
PMid:19251474
28. Jimenez-Soriano Y, Bagan JV. Bisphosphonates, as a new cause of
drug-induced jaw osteonecrosis: An update. Med Oral Patol Oral Cir Bucal.
2005;10:E88-91.
29. Bagan JV, Jiménez Y, Hernández S, Murillo J, Díaz JM,
Poveda R, et al. Osteonecrosis of the jaws by intravenous bisphosphonates and
osteorradionecrosis: a comparative study. Med Oral. 2009; 14: e616-9.
doi:10.4317/medoral.14.e616
30. Bagan JV, Jimenez Y, Diaz JM, Murillo J, Sanchis JM, Poveda R, et al.
Osteonecrosis of the jaws in intravenous bisphosphonate use: Proposal for a
modification of the clinical classification. Oral Oncol. 2009;45:645-6.
doi:10.1016/j.oraloncology.2008.05.011
PMid:18715813
31. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonateinduced exposed
bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition,
prevention, and treatment.J Oral Maxillofac Surg. 2005;63:1567-75.
doi:10.1016/j.joms.2005.07.010
PMid:16243172
32. Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonate therapy.
J Dent Res. 2007;86:1013-21.
doi:10.1177/154405910708601101
PMid:17959890
33. Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of
bisphosphonates: a critical review. Am J Med. 2009;122:S33-45.
doi:10.1016/j.amjmed.2008.12.005
PMid:19187811
34. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis:
risk factors, prediction of risk using serum CTX testing, prevention, and
treatment. J Oral Maxillofac Surg. 2007;65:2397-410.
doi:10.1016/j.joms.2007.08.003
PMid:18022461
35. Fedele S, Kumar N, Davies R, Fiske J, Greening S, Porter S. Dental
management of patients at risk of osteochemonecrosis of the jaws: a critical
review. Oral Dis. 2009;15:527-37.
doi:10.1111/j.1601-0825.2009.01581.x
PMid:19619192
36. Weitzman R, Sauter N, Eriksen EF, Tarassoff PG, Lacerna LV, Dias R, et al.
Critical review: updated recommendations for the prevention, diagnosis, and
treatment of osteonecrosis of the jaw in cancer patients- -May 2006. Crit Rev
Oncol Hematol. 2007;62:148-52.
doi:10.1016/j.critrevonc.2006.12.005
PMid:17336086
37. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, et
al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of
preventive measures in patients with multiple myeloma treated with zoledronic
acid. Ann Oncol. 2009;20:117-20.
doi:10.1093/annonc/mdn554
PMid:18689864
38. Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, et al.
Decreased occurrence of osteonecrosis of the jaw after implementation of dental
preventive measures in solid tumour patients with bone metastases treated with
bisphosphonates. The experience of the National Cancer Institute of Milan. Ann
Oncol. 2009;20:137-45.
doi:10.1093/annonc/mdn526
PMid:18647964
39. Campisi G, Di Fede O, Musciotto A, Lo Casto A, Lo Muzio L, Fulfaro F, et
al. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental
management designs and issues in diagnosis. Ann Oncol. 2007;18:vi168-72.
doi:10.1093/annonc/mdm250
PMid:17591816
40. Flichy-Fernández AJ, Balaguer-Martínez J,
Peñarrocha-Diago M, Bagán JV. Bisphosphonates and dental
implants: current problems. Med Oral Patol Oral Cir Bucal. 2009;14:E355-60.
41. Zahrowski JJ. Bisphosphonate treatment: an orthodontic concern calling for
a proactive approach. Am J Orthod Dentofacial Orthop. 2007;131:311-20.
doi:10.1016/j.ajodo.2006.09.035
PMid:17346585